Michael Krainer Department of Internal Medicine I - Division of Oncology, Comprehensive Cancer Center Medical University of Vienna Biography Publications Institution JoVE Articles Michael Krainer has not added a biography. If you are Michael Krainer and would like to personalize this page please email our Author Liaison for assistance. Publications Loss of HCRP1 Leads to Upregulation of PD-L1 Via STAT3 Activation and is of Prognostic Significance in EGFR-dependent Cancer Translational Research : the Journal of Laboratory and Clinical Medicine. Apr, 2021 | Pubmed ID: 33197651 Impact of Frailty on the Management of Patients with Gynecological Cancer Aged 80 years and Older Archives of Gynecology and Obstetrics. 02, 2021 | Pubmed ID: 33009994 Thirteen-year Analyses of Medical Oncology Outpatient Day Clinic Data: a Changing Field ESMO Open. 10, 2020 | Pubmed ID: 33051192 Erratum to 'Clinical Progression is Associated with Poor Prognosis Whatever the Treatment Line in Metastatic Castration-resistant Prostate Cancer: The CATS International Database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163] European Journal of Cancer (Oxford, England : 1990). Sep, 2020 | Pubmed ID: 32723589 Corrigendum to "Clinical Progression is Associated with Poor Prognosis Whatever the Treatment Line in Metastatic Castration Resistant Prostate Cancer: The CATS International Database" [Eur J Canc 125, (January 2020) 153-163] European Journal of Cancer (Oxford, England : 1990). Sep, 2020 | Pubmed ID: 32605716 Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer Cancers. Feb, 2020 | Pubmed ID: 32120793 Clinical Progression is Associated with Poor Prognosis Whatever the Treatment Line in Metastatic Castration Resistant Prostate Cancer: The CATS International Database European Journal of Cancer (Oxford, England : 1990). 01, 2020 | Pubmed ID: 31787484 Assessment of Body Composition in the Advanced Stage of Castration-resistant Prostate Cancer: Special Focus on Sarcopenia Prostate Cancer and Prostatic Diseases. 06, 2020 | Pubmed ID: 31745255 Synthetic Lethality Guiding Selection of Drug Combinations in Ovarian Cancer PloS One. 2019 | Pubmed ID: 30682083 Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database European Urology Oncology. 12, 2018 | Pubmed ID: 31158090 Synthetic Lethal Combinations of Low-toxicity Drugs for Breast Cancer Identified by Genetic Screens in Yeast Oncotarget. Nov, 2018 | Pubmed ID: 30555636 LUBAC and ABIN-1 Modulate TRAIL-Based NF-κB Induction in Human Embryonic Kidney 293 Cells BioResearch Open Access. 2018 | Pubmed ID: 29862142 Analysis of Hematological Parameters As Prognostic Markers for Toxicity and Survival of Radium Treatment Oncotarget. Mar, 2018 | Pubmed ID: 29662636 Efficacy of Cabazitaxel Rechallenge in Heavily Treated Patients with Metastatic Castration-resistant Prostate Cancer European Journal of Cancer (Oxford, England : 1990). 07, 2018 | Pubmed ID: 29636272 Efficient Leukocyte Depletion by a Novel Microfluidic Platform Enables the Molecular Detection and Characterization of Circulating Tumor Cells Oncotarget. Jan, 2018 | Pubmed ID: 29416657 The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' Field-tested in Infrequent Tumour Entities: an Extended Analysis of Its Feasibility at the Medical University of Vienna ESMO Open. 2017 | Pubmed ID: 28761758 Increased Genitourinary Fistula Rate After Bevacizumab in Recurrent Cervical Cancer Patients Initially Treated with Definitive Radiochemotherapy and Image-guided Adaptive Brachytherapy Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al]. Dec, 2017 | Pubmed ID: 28721510 The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in Daily Practice: a Single Institution, Real-life Experience at the Medical University of Vienna ESMO Open. 2016 | Pubmed ID: 27843624 Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 09, 2016 | Pubmed ID: 27400947 The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma PloS One. 2015 | Pubmed ID: 26248232 Tumor Suppressor Candidate 3 (TUSC3) Prevents the Epithelial-to-mesenchymal Transition and Inhibits Tumor Growth by Modulating the Endoplasmic Reticulum Stress Response in Ovarian Cancer Cells International Journal of Cancer. Sep, 2015 | Pubmed ID: 25735931 HIF1α Regulates MTOR Signaling and Viability of Prostate Cancer Stem Cells Molecular Cancer Research : MCR. Mar, 2015 | Pubmed ID: 25349289 The Potential Evasion of Immune Surveillance in Mucosa Associated Lymphoid Tissue Lymphoma by DcR2-mediated Up-regulation of Nuclear Factor-κB Leukemia & Lymphoma. May, 2015 | Pubmed ID: 25248880 Distinctive Outcome in Patients with Non-uterine and Uterine Leiomyosarcoma BMC Cancer. Dec, 2014 | Pubmed ID: 25523155 Circulating Endothelial Progenitor Cells in Castration Resistant Prostate Cancer: a Randomized, Controlled, Biomarker Study PloS One. 2014 | Pubmed ID: 24755958 TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in Vivo Scientific Reports. Jan, 2014 | Pubmed ID: 24435307 HVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Dec, 2011 | Pubmed ID: 22016507 Recurrence-free Survival in Prostate Cancer is Related to Increased Stromal TRAIL Expression Cancer. Mar, 2011 | Pubmed ID: 21381010 Assessment of a Six Gene Panel for the Molecular Detection of Circulating Tumor Cells in the Blood of Female Cancer Patients BMC Cancer. Dec, 2010 | Pubmed ID: 21129172 Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer Molecular Cancer Therapeutics. Apr, 2010 | Pubmed ID: 20371719 The Role of C-FLIP(L) in Ovarian Cancer: Chaperoning Tumor Cells from Immunosurveillance and Increasing Their Invasive Potential Gynecologic Oncology. Jun, 2010 | Pubmed ID: 20227749 BAMBI is Overexpressed in Ovarian Cancer and Co-translocates with Smads into the Nucleus Upon TGF-beta Treatment Gynecologic Oncology. May, 2010 | Pubmed ID: 20189233 Linking the Ovarian Cancer Transcriptome and Immunome BMC Systems Biology. Jan, 2008 | Pubmed ID: 18173842 A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine As First Line Chemotherapy in Patients with Androgen Independent Prostate Cancer The Journal of Urology. Jun, 2007 | Pubmed ID: 17509302 Promoter Hypermethylation of GSTP1, AR, and 14-3-3sigma in Serum of Prostate Cancer Patients and Its Clinical Relevance The Prostate. Mar, 2007 | Pubmed ID: 17192910 Five Genes from Chromosomal Band 8p22 Are Significantly Down-regulated in Ovarian Carcinoma: N33 and EFA6R Have a Potential Impact on Overall Survival Cancer. Dec, 2005 | Pubmed ID: 16270321 합성 치명적인 상호 작용을 대상으로 하는 약물 조합을 식별 하기 위해 데이터 통합 워크플로우 Maximilian Marhold1, Andreas Heinzel2, Almas Merchant1, Paul Perco3, Michael Krainer1 1Department of Internal Medicine I - Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna, 2Department of Nephrology, Medical University of Vienna, 3Department of Internal Medicine IV, Medical University Innsbruck JoVE 60328 Cancer Research
합성 치명적인 상호 작용을 대상으로 하는 약물 조합을 식별 하기 위해 데이터 통합 워크플로우 Maximilian Marhold1, Andreas Heinzel2, Almas Merchant1, Paul Perco3, Michael Krainer1 1Department of Internal Medicine I - Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna, 2Department of Nephrology, Medical University of Vienna, 3Department of Internal Medicine IV, Medical University Innsbruck JoVE 60328 Cancer Research